600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Closed 07-16 15:00:00
55.99
-1.51
-2.63%
High57.40Low55.51Vol122.01M
Open56.81D1 Closing57.50Amplitude3.29%
Mkt Cap371.61BTradable Cap357.16BTotal Shares6.64B
T/O6.88BT/O Rate1.91%Tradable Shares6.38B
P/B5.84ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Chinese Drugmakers with Big Ambitions Struggle to Recruit Staff for Global Expansion
Reuters  ·  07-16 07:00
Chinese Drugmakers with Big Ambitions Struggle to Recruit Staff for Global Expansion
Hengrui Pharma's HRS-8797 Tablet Receives Clinical Trial Approval Notification
Stock News  ·  07-15 16:52
Hengrui Pharma's HRS-8797 Tablet Receives Clinical Trial Approval Notification
Mingyu Pharma, Led by Hengrui Veteran, Files for Hong Kong IPO Amid Fierce Market Competition
Deep News  ·  07-15 07:21
Mingyu Pharma, Led by Hengrui Veteran, Files for Hong Kong IPO Amid Fierce Market Competition
Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials
MT Newswires Live  ·  07-14 09:44
Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials
Hengrui Pharma's HRS-7058 Capsule Designated as Breakthrough Therapy
Stock News  ·  07-13
Hengrui Pharma's HRS-7058 Capsule Designated as Breakthrough Therapy
Hengrui Pharma's FXI Antibody SHR-2004 Unveils Pivotal Phase III Data at ISTH 2026 LBA Session
Deep News  ·  07-13
Hengrui Pharma's FXI Antibody SHR-2004 Unveils Pivotal Phase III Data at ISTH 2026 LBA Session
Elevar-hengrui Hit with Third FDA Rejection for Liver Cancer Therapy over Manufacturing Concerns
Reuters  ·  07-11
Elevar-hengrui Hit with Third FDA Rejection for Liver Cancer Therapy over Manufacturing Concerns
Hengrui Pharma's Key Drug Iohexol Injection Added to National Essential Medicines List
Stock News  ·  07-10
Hengrui Pharma's Key Drug Iohexol Injection Added to National Essential Medicines List
Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application
Stock News  ·  07-10
Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application
UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation
Stock News  ·  07-09
UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation
Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success
Reuters  ·  07-07
Kailera Shares Tumble on High Nausea Rates Despite Weight-loss Drug's Success
Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma
MT Newswires Live  ·  07-03
Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma
Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30
Stock News  ·  07-02
Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30
Hengrui Pharma Gains Regulatory Nod for Clinical Trials of Three Drug Candidates
Stock News  ·  07-02
Hengrui Pharma Gains Regulatory Nod for Clinical Trials of Three Drug Candidates
Hengrui Pharma Shares Surge Over 6% on New Drug Indication Approval and International Expansion Success
Stock News  ·  07-02
Hengrui Pharma Shares Surge Over 6% on New Drug Indication Approval and International Expansion Success
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
THOMSON REUTERS  ·  06-30
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI
Dow Jones  ·  06-29
Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI
Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%
MT Newswires Live  ·  06-26
Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%
Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication
Stock News  ·  06-25
Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication
Jiangsu Hengrui Pharmaceuticals - Subsidiary Received Notification from Nmpa Approving New Indication for Adebrelimab Injection
THOMSON REUTERS  ·  06-25
Jiangsu Hengrui Pharmaceuticals - Subsidiary Received Notification from Nmpa Approving New Indication for Adebrelimab Injection

Introduction

Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
Issue price:
11.98